Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Cervical Cancer | Research

Effects of metalloprotease ADAMTS12 on cervical cancer cell phenotype and its potential mechanism

Authors: Ruanmin Zou, Ruihong Gu, Xinyu Tu, Jiani Chen, Songjun Liu, Xiangyang Xue, Wensu Li, Yuyang Zhang

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

ADAMTS12 is a gene widely expressed in human tissues. We studied the expression level of ADAMTS12 in cervical cancer tissue and its relationship with clinicopathological features. We also explored the function of ADAMTS12 in cervical cancer cells and its underlying mechanisms. We found the higher expression level of ADAMTS12 in cancer tissues, which was associated with the worse overall survival rate. The immunofluorescence assay showed that the cytoplasm of cervical cancer cells is the main expression site of ADAMTS12. Overexpression of ADAMTS12 in HeLa and CaSki cells prominently promoted the cell proliferation, migration and invasion. We found that 2032 genes were correlated with ADAMTS12, which was mainly related to extracellular matrix, TGF-β signaling pathway. The phosphorylation levels of mTOR and 4E-BP1 were upregulated in ADAMTS12-overexpressing cells. Co-Immunoprecipitation combined with protein mass spectrometry showed that TGF-β signaling pathway-related proteins interacting with ADAMTS12 were screened from HeLa cells with ADAMTS12 overexpression. Therefore, we concluded that ADAMTS12 may affect the mTOR signaling pathway through the interacting with TGF-β1, and then affect the biological function of cervical cancer cells.
Appendix
Available only for authorised users
Literature
1.
2.
Llamazares M, Cal S, Quesada V, López-Otín C. Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. J Biol Chem. 2018;293:11785.CrossRefPubMedPubMedCentral
3.
Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, López-Otín C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002;283:49–62.CrossRefPubMed
4.
5.
6.
Cal S, Arguelles JM, Fernandez PL, López-Otín C. Identification, characterization, and intracellular processing of ADAM-TS12, a novel human disintegrin with a complex structural organization involving multiple thrombospondin-1 repeats. J Biol Chem. 2001;276:17932–40.CrossRefPubMed
7.
8.
Llamazares M, Obaya AJ, Moncada-Pazos A, Heljasvaara R, Espada J, López-Otín C, et al. The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the ras-dependent ERK signalling pathway. J Cell Sci. 2007;120:3544–52.CrossRefPubMed
9.
Moncada-Pazos A, Obaya AJ, Llamazares M, Heljasvaara R, Suárez MF, Colado E, et al. ADAMTS-12 metalloprotease is necessary for normal inflammatory response. J Biol Chem. 2012;287:39554–63.CrossRefPubMedPubMedCentral
10.
Paulissen G, El Hour M, Rocks N, Guéders MM, Bureau F, Foidart J-M, et al. Control of allergen-induced inflammation and hyperresponsiveness by the metalloproteinase ADAMTS-12. J Immunol (Baltimore, Md: 1950). 2012;189:4135–43.
11.
Guo F, Lai Y, Tian Q, Lin EA, Kong L, Liu C. Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheum. 2010;62:2023–36.CrossRefPubMedPubMedCentral
12.
Luan Y, Kong L, Howell DR, Ilalov K, Fajardo M, Bai XH, et al. Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthr Cartil. 2008;16:1413–20.CrossRef
13.
Yu H, Zhu Y. Expression of ADAMTS-7 and ADAMTS-12 in the nucleus pulposus during degeneration of rat caudal intervetebral disc. J Vet Med Sci. 2012;74(1):9–15.CrossRefPubMed
14.
El Hour M, Moncada-Pazos A, Blacher S, Masset A, Cal S, Berndt S, et al. Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene. 2010;29:3025–32.CrossRefPubMed
15.
Bespalova IN, Angelo GW, Ritter BP, Hunter J, Reyes-Rabanillo ML, Siever LJ, et al. Genetic variations in the ADAMTS12 gene are associated with schizophrenia in puerto rican patients of spanish descent. Neuromol Med. 2012;14:53–64.CrossRef
16.
Carré G-A, Couty I, Hennequet-Antier C, Govoroun MS. Gene expression profiling reveals new potential players of gonad differentiation in the chicken embryo. PLoS ONE. 2011;6:e23959.CrossRefPubMedPubMedCentral
17.
Fontanil T, Rúa S, Llamazares M, Moncada-Pazos A, Quirós PM, García-Suárez O, et al. Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget. 2014;5:1253–64.CrossRefPubMedPubMedCentral
18.
Moncada-Pazos A, Obaya AJ, Fraga MF, Viloria CG, Capellá G, Gausachs M, et al. The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J Cell Sci. 2009;122:2906–13.CrossRefPubMed
19.
Li X, Xiao X, Chang R, Zhang C. Comprehensive bioinformatics analysis identifies lncRNA HCG22 as a migration inhibitor in esophageal squamous cell carcinoma. J Cell Biochem. 2020;121:468–81.CrossRefPubMed
20.
Mariani A, Wang C, Oberg AL, Riska SM, Torres M, Kumka J, et al. Genes associated with bowel metastases in ovarian cancer. Gynecol Oncol. 2019;154:495–504.CrossRefPubMedPubMedCentral
21.
Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, et al. Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Ann Oncol. 2017;28:604–10.CrossRef
22.
Xue C, Li G, Lu J, Li L. Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. Signal Transduct Target Ther. 2021;6:400.CrossRefPubMedPubMedCentral
23.
Karlsson E, Pérez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 2013;15:R96.CrossRefPubMedPubMedCentral
24.
Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435–57.CrossRefPubMed
25.
Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31:220–7.CrossRefPubMedPubMedCentral
26.
Drabsch Y, ten Dijke P. TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31:553–68.CrossRefPubMed
27.
de Gregorio A, Widschwendter P, Ebner F, Friedl TWP, Huober J, Janni W, et al. Influence of the New FIGO classification for cervical Cancer on patient survival: a retrospective analysis of 265 histologically confirmed cases with FIGO Stages IA to IIB. Oncology. 2020;98:91–7.CrossRefPubMed
28.
Matsuo K, Mandelbaum RS, Machida H, Purushotham S, Grubbs BH, Roman LD, et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. J Gynecologic Oncol. 2018;29:e91.CrossRef
29.
Gai J, Wang X, Meng Y, Xu Z, Kou M, Liu Y. Clinicopathological factors influencing the prognosis of cervical cancer. J BUON: Official J Balkan Union Oncol. 2019;24:291–5.
30.
Rogers L, Siu SSN, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012;5:CD007583.PubMed
31.
Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet (London England). 1997;350:535–40.CrossRefPubMed
32.
Lee WK, Chong GO, Jeong SY, Lee HJ, Park S-H, Ryu JM, et al. Prognosis-predicting model based on [F]fluorodeoxyglucose PET metabolic parameters in locally advanced cervical cancer patients treated with concurrent chemoradiotherapy: multi-center retrospective study. J Clin Med. 2020;9:427.CrossRefPubMedPubMedCentral
33.
Zhang Y, Hu Y, Zhao S, Cui C. The utility of PET/CT metabolic parameters measured based on fixed percentage threshold of SUVmax and adaptive iterative algorithm in the New revised FIGO Staging System for Stage III Cervical Cancer. Front Med. 2021;8:680072.CrossRef
34.
Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer. 2010;116:1469–75.CrossRefPubMed
35.
Katz LH, Likhter M, Jogunoori W, Belkin M, Ohshiro K, Mishra L. TGF-β signaling in liver and gastrointestinal cancers. Cancer Lett. 2016;379:166–72.CrossRefPubMedPubMedCentral
36.
Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Sem Cancer Biol. 2019;59:125–32.CrossRef
37.
Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biology: CB. 2003;13:797–806.CrossRefPubMed
38.
Arruda MA, Rossi AG, de Freitas MS, Barja-Fidalgo C, Graça-Souza AV. Heme inhibits human neutrophil apoptosis: involvement of phosphoinositide 3-kinase, MAPK, and NF-kappaB. J Immunol (Baltimore, Md: 1950). 2004;173:2023–30.
39.
Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudla B. Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. Endokrynol Pol. 2013;64:384–96.CrossRef
40.
Birrer MJ, Fujiwara K, Oaknin A, Randall L, Ojalvo LS, Valencia C, et al. The changing landscape of systemic treatment for cervical cancer: rationale for inhibition of the TGF-beta and PD-L1 pathways. Front Oncol. 2022;12:814169.CrossRefPubMed
Metadata
Title
Effects of metalloprotease ADAMTS12 on cervical cancer cell phenotype and its potential mechanism
Authors
Ruanmin Zou
Ruihong Gu
Xinyu Tu
Jiani Chen
Songjun Liu
Xiangyang Xue
Wensu Li
Yuyang Zhang
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00776-2

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma

Research

Evaluation of the relationship between Ki67 expression level and neoadjuvant treatment response and prognosis in breast cancer based on the Neo-Bioscore staging system

Review

Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review

Research

Effect of microserum environment stimulation on extraction and biological function of colorectal cancer stem cells

Research

High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

Research

Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits